NF2 and meningioma: We further show that the selective mTOR kinase inhibitor AZD2014, targeting both mTORC1 and mTORC2, is more efficient than rapamycin in blocking proliferation of primary human meningioma cells and thus may hold promise as a more effective therapeutic option for NF2 patients.